Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × Loperamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Diarrhea 4 Rectal Neoplasms 3 Sarcoma, Alveolar Soft Part 2 Ovarian Neoplasms 2 Vulvar Neoplasms 1 Vulvar Diseases 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urogenital Neoplasms 1 Triple Negative Breast Neoplasms 1 Short Bowel Syndrome 1 Recurrence 1 Papillomavirus Infections 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Low Anterior Resection Syndrome 1 Gliosarcoma 1 Glioblastoma 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colorectal Cancer Metastatic 1 Colonic Neoplasms 1 Colitis, Ulcerative 1 Colitis 1 Chondrosarcoma 1 Chemotherapy-related Diarrhea 1

Interventions

pembrolizumab 127 Carboplatin 111 Paclitaxel 94 Cyclophosphamide 73 Capecitabine 53 130-nm albumin-bound paclitaxel 52 Doxorubicin 42 Gemcitabine 38 Albumin-Bound Paclitaxel 33 atezolizumab 32 Taxes 32 Nivolumab 29 Cisplatin 29 Docetaxel 28 sacituzumab govitecan 27 Epirubicin 25 Specimen Handling 24 Bevacizumab 24 eribulin 23 olaparib 22 durvalumab 21 Magnetic Resonance Spectroscopy 21 Drug Therapy 21 Biopsy 21 camrelizumab 19 toripalimab 17 Everolimus 13 veliparib 12 spartalizumab 12 liposomal doxorubicin 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05520723 2025-12-04

PRIMED

MedSIR

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡